Blog
RSS FeedPosted by Michael Wonder on 13 Nov 2019
ICER finalises method adaptations for assessing potential cures and other high-impact single or short-term therapies
12 November 2019 - Collaborative project with NICE and CADTH leads to important adaptations for ICER’s methods including creation of optimistic ...
Posted by Michael Wonder on 11 Oct 2019
ICER releases updated draft evidence report on rheumatoid arthritis therapies
11 October 2019 - Public comment period extended through 8 November 2019; public meeting now to take place on 9 December ...
Posted by Michael Wonder on 26 Sep 2019
ICER releases draft evidence report on rheumatoid arthritis therapies
26 September 2019 - Public comment period now open until 24 October 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 12 Sep 2019
ICER publishes evidence report on additive cardiovascular disease therapies
12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...
Posted by Michael Wonder on 11 Sep 2019
ICER releases draft evidence report on diabetes therapies
11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting ...
Posted by Michael Wonder on 24 Jul 2019
ICER releases draft evidence report on additive cardiovascular disease therapies
24 July 2019 - Public comment period now open until 20 August 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 09 Jul 2019
Institute for Clinical and Economic Review lists potential topics for assessments in 2020
9 July 2019 - The Institute for Clinical and Economic Review has released its preliminary list of potential assessment topics ...
Posted by Michael Wonder on 11 Apr 2019
Institute for Clinical and Economic Review posts draft scoping document for the assessment of treatments for rheumatoid arthritis
11 April 2019 - Document open to public comment until 1 May 2019. ...
Posted by Michael Wonder on 09 Apr 2019
Institute for Clinical and Economic Review releases draft evidence report on treatments for peanut allergy
9 April 2019 - Public comment period now open until 8 May 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 17 Mar 2019
On the use of list prices in drug pricing research
14 March 2019 - In the limitations section of this article, we discussed in detail that list prices do not capture ...
Posted by Michael Wonder on 12 Mar 2019
Institute for Clinical and Economic Review publishes white paper on alternative models for pharmaceutical rebates
12 March 2019 - Paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future ...
Posted by Michael Wonder on 25 Sep 2018
ICER releases draft evidence report on biologic treatments for asthma
24 September 2018 - Public comment period now open until 22 October 2018; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 02 Aug 2018
Institute for Clinical and Economic Review lists potential options for assessments in 2019
2 August 2018 - ICER will select 2019 topics from a wide range of treatments, medical devices, and IT-based interventions. ...
Posted by Michael Wonder on 20 Jul 2018
ICER releases draft evidence report on inotersen and patisiran for hereditary transthyretin amyloidosis
20 July 2018 - Public comment period now open until 17 August; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 12 Jul 2018
ICER releases draft evidence report on anti-androgen therapies for non-metastatic castration-resistant prostate cancer
12 July 2018 - Public comment period now open until 9 August; requests to make oral comment during public meeting also ...